Statin labelling may overstate adverse events
Drug and Therapeutics Bulletin · 2026-05 · 64 (5) · 70-70
DOI: 10.1136/dtb.2026.000016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Therapeutics Bulletin, online erschienen am 29.04.2026. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug Labeling. Die Arbeit nennt 5 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Overview of: Cholesterol Treatment Trialists’ (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet 2026;407(10529):689-703.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2026). Statin labelling may overstate adverse events. Drug and Therapeutics Bulletin, 64(5), 70-70. https://doi.org/10.1136/dtb.2026.000016
Vancouver
Statin labelling may overstate adverse events. Drug and Therapeutics Bulletin. 2026;64(5):70-70. doi:10.1136/dtb.2026.000016
BibTeX
@article{euvimed2026,
title = {Statin labelling may overstate adverse events},
journal = {Drug and Therapeutics Bulletin},
year = {2026},
volume = {64},
number = {5},
pages = {70--70},
doi = {10.1136/dtb.2026.000016}
}
EUVIMED